Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver. MB07133 is
being developed for the treatment of inoperable HCC, using a platform technology known as
HepDirectTM, which enables drugs to be targeted specifically to the liver. The objective for
this study is to determine the safety and tolerability of MB07133.